ArticleCase reports in infectious diseases2026
HIV-Associated Diffuse Large B-Cell Lymphoma Treated With Outpatient Pola-R-CHP Without Antiretroviral Therapy Modification: A Case Report.
Article in Case reports in infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HIV-Associated Diffuse Large B-Cell Lymphoma Treated With Outpatient Pola-R-CHP Without Antiretroviral Therapy Modification: A Case Report.Case reports in infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: People living with HIV (PLWH) remain at increased risk of diffuse large B-cell lymphoma (DLBCL). Polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) has emerged as a standard first-line option for DLBCL in the general population, but the pivotal POLARIX trial excluded PLWH, leaving limited evidence on feasibility with contemporary antiretroviral therapy (ART). Case Presentation: A 61-year-old man presented with progressive anorexia and weight loss. With durable virologic suppression (plasma HIV-1 RNA below 20 copies/mL) and immune reconstitution (CD4+ T-cell count approximately 300 cells/µL) on bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF), he was diagnosed with nongerminal center B-cell DLBCL (Lugano stage II; International Prognostic Index score 2). Pola-R-CHP was administered every 21 days for six cycles (Cycle 1: inpatient and Cycles 2-6: outpatient), followed by two additional rituximab cycles, without ART modification. No grade 3-4 nonhematologic toxicity, febrile neutropenia, or serious infections occurred. HIV-1 RNA remained below 20 copies/mL throughout treatment, and CD4+ T-cell counts showed no clinically meaningful decline. End-of-treatment fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET-CT) demonstrated a partial metabolic response with two small residual FDG-avid foci (∼1 cm; SUVmax ∼4-5). At the last follow-up, the patient had no clinical or radiologic evidence of progression. Conclusion: Outpatient-delivered Pola-R-CHP appeared feasible in PLWH with virologic suppression and immune reconstitution receiving BIC/FTC/TAF, without virologic breakthrough or unexpected toxicity. Prospective inclusion of PLWH in polatuzumab-containing frontline studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.